Showing results (221-230 of 342) with videos related to

Sort By:
Pageof 35
Journal of Clinical Medicine|August 26, 2023
A Deep-Learning Approach to Spleen Volume Estimation in Patients with Gaucher DiseaseIdo Azuri, Ameer Wattad, Keren Peri-Hanania, et al.
The Journal of Clinical Investigation|October 2, 2015
Proof-of-principle rapid noninvasive prenatal diagnosis of autosomal recessive founder mutationsDavid A Zeevi, Gheona Altarescu, Ariella Weinberg-Shukron, et al.
American Journal of Hematology|March 18, 2015
Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher diseaseDeborah Elstein, Atul Mehta, Derralynn A Hughes, et al.
British Journal of Haematology|October 2, 2014
The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemiaAshish Banerjee, Nicole A Mifsud, Robert Bird, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 1, 2017
Activity and Capacity Profile of Transplant Physicians and Centers in Australia and New ZealandIan Nivison-Smith, Samuel Milliken, Anthony J Dodds, et al.
Internal Medicine Journal|June 6, 2022
Predictors and outcomes of dose reduction of methotrexate and cyclosporin graft-versus-host disease prophylaxis following allogeneic haemopoietic cell transplantationRadha Ramanan, Andrew B M Lim, Joanne L C Tan, et al.
Advances in Therapy|October 22, 2022
Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-UpMustafa N Yenerel, Flore Sicre de Fontbrune, Caroline Piatek, et al.
Blood Cells, Molecules & Diseases|August 9, 2016
Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher diseaseAri Zimran, Gloria Durán, Pilar Giraldo, et al.
American Journal of Hematology|February 7, 2013
Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 studyDerlis E Gonzalez, Hadhami Ben Turkia, Elena A Lukina, et al.
American Journal of Hematology|November 2, 2017
Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)Ari Zimran, Nadia Belmatoug, Bruno Bembi, et al.
Pageof 35